Eupraxia Pharmaceuticals reported a net loss of $14.5 million for the second quarter of 2026, outperforming analyst expectations for the period. As a clinical-stage biotechnology firm, the company recorded zero revenue while significantly ramping up its clinical development efforts. Liquidity remains strong following a February capital raise, providing a substantial buffer for the lead EP-104GI program as it progresses through pivotal trials.
Key Highlights
- Research and development expenses increased to $12.8 million from $5.2 million in the prior-year period, driven primarily by Phase 2b trial activity.
- Total liquidity reached $133.7 million, comprised of $52.4 million in cash and $81.2 million in short-term investments, bolstered by a $58.6 million net raise in early 2026.
- Direct external costs for the lead product candidate, EP-104GI, totaled $6.9 million for the quarter, representing more than half of the total R&D spend.